Johnson & Johnson (JNJ) Balance Sheet

The balance sheet has expanded steadily, driven by acquisitions and organic growth, but the pace of asset growth has outpaced equity growth, leading to a gradual increase in leverage. This suggests management is comfortable using debt to fund strategic initiatives, though the trend warrants monitoring for potential overextension.

JNJ's debt levels are moderate relative to peers like Pfizer (D/E 0.78) and Merck (0.96), and the recent reduction suggests a strategic approach to capital structure. The company's strong cash generation and investment-grade profile likely support refinancing flexibility, but investors should monitor the absolute debt level given its size.

The significant increase in goodwill, likely from acquisitions, raises the risk of future impairment if acquired businesses underperform. The volatility in PPE, with a spike to $54.7B in 2026Q1, may reflect reclassifications or acquisitions, but the overall trend suggests a shift toward intangible value creation, which could be less predictable.

The consistent growth in retained earnings, despite quarterly net income volatility, underscores the company's ability to reinvest in the business and support shareholder returns. However, the equity growth is modest relative to asset growth, suggesting that debt and other liabilities are absorbing a larger share of the balance sheet expansion.

JNJ's liquidity position is adequate but not exceptional, with a current ratio below 1.2 for most quarters. The cash balance, while substantial, is lower than peers like Merck ($14.6B) relative to size, but the company's strong operating cash flow provides additional flexibility. The decline from the 2025Q1 cash spike suggests deployment into investments or debt reduction.